Vitamin E for people with non-alcoholic fatty liver disease

Wen, Hong-Zhu; Deng, Hongyu; Yang, Lili; Li, Lujin; J, Lin; Zheng, Peiyong; Ji, Guang

doi:10.1002/14651858.cd015033

Cited by 2 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin E at a dose of 800 IU daily has been associated with amelioration in steatosis and inflammation as well as a reduction in serum ALT levels. However, high doses of vitamin E have been alleged to be related to increased all-cause mortality in a minority of studies [97]. In addition, it is noteworthy that high doses of vitamin E have also been associated with an increased risk of bleeding, a point that should be of particular concern for patients with NAFLD and cirrhosis, while a plausible relationship between prostate cancer and high doses of vitamin E has been reported as well [97].…”

Section: Nafld Treatment Optionsmentioning

confidence: 99%

“…However, high doses of vitamin E have been alleged to be related to increased all-cause mortality in a minority of studies [97]. In addition, it is noteworthy that high doses of vitamin E have also been associated with an increased risk of bleeding, a point that should be of particular concern for patients with NAFLD and cirrhosis, while a plausible relationship between prostate cancer and high doses of vitamin E has been reported as well [97]. Nevertheless, the impact of confounding factors, such as the concurrent use of other nutraceuticals, could account for these discrepancies among various studies [1].…”

Section: Nafld Treatment Optionsmentioning

confidence: 99%

See 1 more Smart Citation

NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics

Kounatidis,

Vallianou,

Geladari

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a major public health issue worldwide. It is the most common liver disease in Western countries, andits global prevalence is estimated to be up to 35%. However, its diagnosis may be elusive, because liver biopsy is relatively rarely performed and usually only in advanced stages of the disease. Therefore, several non-invasive scores may be applied to more easily diagnose and monitor NAFLD. In this review, we discuss the various biomarkers and imaging scores that could be useful in diagnosing and managing NAFLD. Despite the fact that general measures, such as abstinence from alcohol and modulation of other cardiovascular disease risk factors, should be applied, the mainstay of prevention and management is weight loss. Bariatric surgery may be suggested as a means to confront NAFLD. In addition, pharmacological treatment with GLP-1 analogues or the GIP agonist tirzepatide may be advisable. In this review, we focus on the utility of GLP-1 analogues and GIP agonists in lowering body weight, their pharmaceutical potential, and their safety profile, as already evidenced inanimal and human studies. We also elaborate on other options, such as the use of vitamin E, probiotics, especially next-generation probiotics, and prebiotics in this context. Finally, we explore future perspectives regarding the administration of GLP-1 analogues, GIP agonists, and probiotics/prebiotics as a means to prevent and combat NAFLD. The newest drugs pegozafermin and resmetiron, which seem to be very promising, arealso discussed.

show abstract

Section: Nafld Treatment Optionsmentioning

confidence: 99%

Section: Nafld Treatment Optionsmentioning

confidence: 99%

NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics

Kounatidis,

Vallianou,

Geladari

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

Vitamin E for people with non-alcoholic fatty liver disease

Wen,

Deng,

Yang

et al. 2024

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Rationale Non‐alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction‐associated steatotic liver disease (MASLD), is the most common liver disease worldwide, affecting an estimated 3 in 10 people. The available treatment is far from optimal. Diet and lifestyle changes to promote weight loss and weight loss maintenance are the basic management of NAFLD, but these are difficult to achieve and maintain. Vitamin E has shown beneficial effects on oxidative stress, which plays a major role in the pathogenesis of NAFLD. However, there is uncertainty about the effects of vitamin E for people with NAFLD. Objectives To evaluate the beneficial and harmful effects of vitamin E alone, or vitamin E in combination with other vitamins or minerals, versus placebo or no intervention in people with NAFLD. Search methods We used recommended Cochrane search methods. The latest search was performed on 2 February 2024. Eligibility criteria We included randomised clinical trials that compared vitamin E alone, or in combination with other vitamins or minerals, at any dose, duration, and route of administration, versus placebo or no intervention, in people with NAFLD of any age, sex, or ethnic origin. We included participants with imaging techniques or histology‐proven NAFLD and minimal alcohol intake, and participants with steatohepatitis who had liver biopsies. Outcomes Our critical outcomes were all‐cause mortality, liver‐related mortality, and serious adverse events. Our important outcomes were liver‐related morbidity, health‐related quality of life, non‐serious adverse events, biochemical response, and imaging assessment of the degree of fatty liver. Risk of bias We used Cochrane's RoB 2 tool to assess risk of bias for each of the predefined outcomes. Synthesis methods We used standard Cochrane methods. We used GRADE to assess the certainty of evidence. Included studies We included 16 randomised clinical trials involving 1066 paediatric and adult participants with NAFLD. Experimental groups received vitamin E alone (14 trials) or vitamin E in combination with vitamin C (2 trials). Control groups received placebo in 13 trials and no intervention in three trials. Daily dosages of oral vitamin E ranged from 298 international units (IU) to 1000 IU. Co‐interventions were lifestyle and low‐calorie diet interventions in 13 trials, ursodeoxycholic acid in one trial, unchanged diet and physical activity in one trial, and baseline treatments for type 2 diabetes in one trial. Nine trials had more than two intervention groups, but we used only the groups in which vitamin E alone or vitamin E in combination with vitamin C were compared with placebo or no intervention. In total, 7.9% (84/1066) of participants dropped out. Follow‐up ranged from 2 months to 24 months. Synthesis of...

show abstract

Vitamin E for people with non-alcoholic fatty liver disease

Cited by 2 publications

References 62 publications

NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics

NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics

Vitamin E for people with non-alcoholic fatty liver disease

Contact Info

Product

Resources

About